100 Clinical Results associated with Measles Vaccine,Live(Shanghai Institute of Biological Products Co., Ltd.)
100 Translational Medicine associated with Measles Vaccine,Live(Shanghai Institute of Biological Products Co., Ltd.)
100 Patents (Medical) associated with Measles Vaccine,Live(Shanghai Institute of Biological Products Co., Ltd.)
1
Literatures (Medical) associated with Measles Vaccine,Live(Shanghai Institute of Biological Products Co., Ltd.)01 Jan 1979·Transactions of the Royal Society of Tropical Medicine and HygieneQ4 · MEDICINE
Immunization against measles in children at risk for severe disease
Q4 · MEDICINE
Article
Author: A.R. Watson ; A. Wesley ; H.M. Coovadia
Live measles vaccine induced protective levels of antibody in 70% of children with protein-calorie-malnutrition (PCM) within 21 days and possibly in 90% by 42 days. The development of specific antibody was delayed and symptoms due to the vaccine more frequent (64%) in these children than in healthy children. Administration of measles vaccine may have predisposed to an associated fatal pneumonia in one malnourished child. Human measles hyperimmune globulin can maintain adequate antibody levels in most children with PCM (75%) for at least three to four weeks. Vaccination induced protective levels of measles antibody in 83% of healthy children under 10 months of age, which compared well with 86% of successful immunizations done at 10 months or later. There was wastage of vaccine in 40 to 70% of children who, despite a negative history of measles, had protective levels of antibody when admitted to the study. It is suggested that malnourished children in the community or the very young can be safely and effectively vaccinated against measles. But passive immunization is preferred in children with PCM severe enough to be admitted to hospital and thereby at increased risk of exposure to measles and other infections.
100 Deals associated with Measles Vaccine,Live(Shanghai Institute of Biological Products Co., Ltd.)